Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

ACTIVE NOT RECRUITING NA

The LEADLESS II IDE Study for the Aveir VR Leadless Pacemaker System

NCT04559945 · View on ClinicalTrials.gov ↗

Study Summary

prospective, non-randomized, multi-center, international clinical study is designed to confirm the safety and effectiveness of the Aveir LP System in a subject population indicated for a VVI(R) pacemaker.

Interventions

  • DEVICE Aveir VR Leadless Pacemaker System

Study Locations (20)

California

  • University of Southern California — Long Beach
  • Premier Cardiology Inc — Newport Beach
  • Huntington Memorial Hospital — Pasadena

Kentucky

  • St. Elizabeth Medical Center - South Unit — Edgewood
  • Baptist Health Lexington — Lexington
  • University of Kentucky — Lexington

Alabama

  • University Hospital - University of Alabama at Birmingham (UAB) — Birmingham
  • The Heart Center PC — Huntsville

Florida

  • Naples Heart Rhythm Specialists PA — Naples
  • Orlando Health — Orlando

Georgia

  • Piedmont Athens Regional Medical Center — Athens
  • Redmond Regional Medical Center — Rome

Kansas

  • Kansas University Medical Center — Kansas City
  • Kansas City Cardiac Arrhythmia Research Foundation — Overland Park

Michigan

  • Ascension St. John Hospital — Detroit
  • Sparrow Clinical Research Institute — Lansing

Arizona

  • Honor Health — Scottsdale

Trial Details

FieldValue
Enrollment Target 326 participants
Start Date 2020-11-13
Est. Completion 2023-08-31
Phase NA

Sponsor

Abbott Medical Devices

155 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04559945

The ClinicalTrials.gov registry entry for NCT04559945 describes a study currently listed as active not recruiting. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 326 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abbott Medical Devices, which has 155 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 2 conditions, with Bradycardia appearing as the primary indexed condition, and to 1 intervention — of which Aveir VR Leadless Pacemaker System is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT04559945 reports 20 study locations spanning 11 distinct geographic areas — top geographies include California, Kentucky, Alabama. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT04559945 about?

NCT04559945 is a clinical study titled "The LEADLESS II IDE Study for the Aveir VR Leadless Pacemaker System". prospective, non-randomized, multi-center, international clinical study is designed to confirm the safety and effectiveness of the Aveir LP System in a subject population indicated for a VVI(R) pacemaker.

What is the current status of trial NCT04559945?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 326 participants. The study started on 2020-11-13. Estimated completion is 2023-08-31.

What conditions does trial NCT04559945 study?

This clinical trial studies the following conditions: Bradycardia, Cardiac Rhythm Disorder. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT04559945?

The interventions under investigation include: Aveir VR Leadless Pacemaker System (DEVICE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT04559945?

This trial is sponsored by Abbott Medical Devices, which has 155 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT04559945 being conducted?

This trial has 20 study locations across Alabama, Arizona, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial